StreetInsider.com News Articles

Annovis Bio regains NYSE listing compliance

Tue, 26 May 2026 08:01:09 -0400

Annovis Bio Inc. (NYSE: ANVS) announced it has regained compliance with New York Stock Exchange continued listing standards after falling below required thresholds in 2025.

The biotechnology company received notice from the NYSE on March 26, 2025, that it was not compliant with Section 802.01B of the NYSE Listed Company Manual. The company's average global market capitalization had fallen below $50 million over a consecutive 30-trading-day period while its stockholders' equity was also below $50 million.

The NYSE accepted Annovis's plan to regain compliance on June 19, 2025, and granted an 18-month cure period from the original notice date. The company executed

Annovis Bio Regains NYSE Listing Compliance

Tue, 26 May 2026 08:00:00 -0400

MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today that it has regained compliance with the New York Stock Exchange (NYSE) continued listing standards.

On March 26, 2025, the NYSE notified Annovis of its non-compliance with Section 802.01B of the NYSE Listed Company Manual, as the Company's average global market capitalization had fallen below $50 million over a consecutive 30-trading-day period

Annovis Bio Regains NYSE Listing Compliance

Tue, 26 May 2026 08:00:00 -0400

Annovis Bio Regains NYSE Listing Compliance

Tue, 26 May 2026 08:00:00 -0400

Annovis Bio Regains NYSE Listing Compliance

Tue, 26 May 2026 08:00:00 -0400

Form 4 Annovis Bio, Inc. For: May 20 Filed by: Hoffman Michael B

Thu, 21 May 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260521/26537457.html

Form 4 Annovis Bio, Inc. For: May 20 Filed by: Hoffman Michael B

Thu, 21 May 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260521/26537457.html

Form 8-K Annovis Bio, Inc. For: May 20

Wed, 20 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260520/26528580.html

Form 8-K Annovis Bio, Inc. For: May 20

Wed, 20 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260520/26528580.html

Form 424B5 Annovis Bio, Inc.

Wed, 20 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260520/26528454.html

Form 424B5 Annovis Bio, Inc.

Wed, 20 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260520/26528454.html

Annovis Bio prices $15 million public offering at $1.90 per share

Wed, 20 May 2026 08:01:34 -0400

Annovis Bio Inc. (NYSE: ANVS) announced the pricing of a $15 million underwritten public offering of common stock and warrants. The biotechnology company will sell 7,895,000 shares of common stock with accompanying warrants to purchase up to 7,105,500 additional shares at a combined price of $1.90 per unit.

Each warrant carries an exercise price of $2.25 per share, becomes exercisable immediately upon issuance, and expires six years from the date of issuance. The shares and warrants will be issued separately but must be purchased together in the offering.

The company expects to receive approximately $15 million in gross proceeds before deducting underwriting

Annovis Bio prices $15 million public offering at $1.90 per share

Wed, 20 May 2026 08:01:34 -0400

The company expects to receive approximately $15 million in gross proceeds before deducting underwriting

Annovis Bio prices $15 million public offering at $1.90 per share

Wed, 20 May 2026 08:01:34 -0400

The company expects to receive approximately $15 million in gross proceeds before deducting underwriting

Annovis Bio prices $15 million public offering at $1.90 per share

Wed, 20 May 2026 08:01:34 -0400

The company expects to receive approximately $15 million in gross proceeds before deducting underwriting

Annovis Bio prices $15 million public offering at $1.90 per share

Wed, 20 May 2026 08:01:34 -0400

The company expects to receive approximately $15 million in gross proceeds before deducting underwriting

Annovis Bio prices $15 million public offering at $1.90 per share

Wed, 20 May 2026 08:01:34 -0400

The company expects to receive approximately $15 million in gross proceeds before deducting underwriting

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants